Area 23
A revenue increase of 60% to more than $85 million last year pushed Area 23 into the large agency category.
Those numbers are especially impressive given the agency absorbed a $22 million loss after Novavax’s RSV vaccine failed its Phase III study and Lilly’s promising Alzheimer’s compound also fell short.
Judges were clearly impressed by the growth, but they also praised the agency’s highly respected management team and its very provocative work.
Client testimonials also expressed high regard for the firm’s creative work, as well as its creative thinking, passion, and commitment. Certainly, Area 23 delivered powerful work to a variety of clients last year.
It launched more than 12 products and won six out of six pitches.
Work highlights included three oncology launches, Merrimack’s Onivyde, Lilly’s Lartruvo, Roche/Genentech’s Alecensa, and the relaunch of diabetes treatment Jardiance after it won a cardiovascular indication.
Breakthrough, exceptional nonprofit work included the Mr. Sun video for the Mollie Biggane Melanoma Foundation; The Hardest Crossword for the Alzheimer’s Foundation of America; and Speaking Fireworks to help war veterans with PTSD.
Judges also appreciated that Area 23 expanded areas of competency. For example, it introduced a new regulatory operations core competency; a new payer and health systems strategic offering; and a technology and engineering group, which made the Speaking Fireworks and Purell Cooties Catcher campaigns a reality.
From the October 19, 2017 Issue of MM+M - Medical Marketing and Media
